Sasmar Pharmaceuticals acquires Chicago-based Aquatrove
Sasmar Pharmaceuticals, a Belgium-based pharmaceutical manufacturer, has acquired Aquatrove Biosciences this week as it continues to expand its portfolio of biotechnology companies that will help improve its product pipeline.
Aquatrove, based in Chicago, focuses on the discovery, research and development of human reproductive health and fertility.
As part of the acquisition, Sasmar has acquired all of Aquatrove’s privately held stock in exchange for an upfront payment of cash, Sasmar said in a statement. The exact amount has not been disclosed.
Additionally, Sasmar has acquired Aquatrove’s entire portfolio, patents and ownership of research data it has been compiling for the last 14 years.
“The acquisition captures the capability and know-how built up over many years by the specialized team at Aquatrove and facilitates the realization of our plans for growth moving forward,” said Sasmar’s president and CEO John-Michael Mancini in a statement.
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.